A Locke Lord team represented Biohaven Pharmaceutical Holding Company Ltd. in its completion of an oversubscribed $80 million private financing, announced on Nov. 1, 2016. According to the Biohaven press release, this financing will be used to advance the company’s late stage clinical pipeline and advance new therapies into clinical trials. The round was led by Venrock along with other leading biotech investors, including RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital. Two undisclosed blue chip pharmaceutical companies also participated in the round as part of in-licensing agreements with Biohaven. The Locke Lord team was led by Douglas Gray (Providence) with assistance from Tamer Tullgren (Chicago) and Ralph Loren (Boston).
Posted November 9, 2016